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*Patients were considered to be at high risk of relapse following
transplant if the indication for transplant was one of these diag-
noses: AML other than 1st remission, CML other than CP; ALL;
APL; and lymphoma. Patients with other diagnoses were consid-
ered to be at low risk. The variable for BDP was deﬁned in the
model as a time dependent covariate. The hazard ratio was esti-
mated for each variable from a multivariate Cox model.
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Mesenchymal stem cells (MSC) derived from adult bone marrow
can differentiate into several mesenchymal tissues and they also
have immunomodulatory effects. We gave MSC to eight patients
with steroid-refractory grades III-IV acute graft-versus-host dis-
ease (GVHD) and one who had extensive chronic GVHD. The
MSC dose was median 1.0 (range 0.7 to 9)  106/kg body weight
of the recipient. No acute side-effects occurred after the MSC
infusions. Six patients were treated once, three patients twice,
one was given a second infusion for a recurrence of GVHD and
two showed a poor response shortly after the ﬁrst infusion. Two
patients received MSC from HLA-identical siblings, six from
haplo-identical family donors and four from unrelated mis-
matched donors. Acute GVHD disappeared completely in six of
eight patients. One of these developed cytomegalovirus gastro-
enteritis. Two died soon after this treatment and therefore the
response could not be evaluated, but one had MSC donor DNA
in the colon and a lymph node. Five patients are still alive
between 2 months and 3 years after the transplantation. Their
survival rate was signiﬁcantly better than that of 16 patients with
steroid-resistant biopsy-proven gastrointestinal GVHD, not
treated with MSC during the same period (P  .03). One patient
treated for extensive chronic GVHD showed a transient re-
sponse in the liver, but not in the skin and he died of Epstein-
Barr virus lymphoma. In conclusion, MSC is a very promising
treatment for severe steroid-resistant acute GVHD.
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